Enhancing Incretin Action for the Treatment of Type 2 Diabetes, Diabetes Care, vol.26, issue.10, pp.2929-2969, 2003. ,
DOI : 10.2337/diacare.26.10.2929
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, The Lancet, vol.368, issue.9548, pp.1696-705, 2006. ,
DOI : 10.1016/S0140-6736(06)69705-5
Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study, Diabetologia, vol.180, issue.9, pp.1732-1776, 2009. ,
DOI : 10.1007/s00125-009-1418-4
Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group, Diabetologia, vol.40, issue.9, pp.1755-65, 2009. ,
DOI : 10.1007/s00125-009-1453-1
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes, Diabetologia, vol.23, issue.9, pp.1766-77, 2009. ,
DOI : 10.1007/s00125-009-1440-6
Insulin glargine use and short-term incidence of malignancies???a population-based follow-up study in Sweden, Diabetologia, vol.14, issue.9, pp.1745-54, 2009. ,
DOI : 10.1007/s00125-009-1444-2
Risk of Stroke with Thiazolidinediones: A Ten-Year Nationwide Population-Based Cohort Study, Cerebrovascular Diseases, vol.36, issue.2, pp.145-51, 2013. ,
DOI : 10.1159/000353679
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) http://care.diabetesjournals.org/content/early, 2012. ,
http://www.invs.sante.fr/publications, 2010. ,
The Physiology of Glucagon-like Peptide 1, Physiological Reviews, vol.87, issue.4, 2007. ,
DOI : 10.1152/physrev.00034.2006
4 : homéostasie glucidique et diabète de type 2 ,
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes, Current Medical Research and Opinion, vol.23, issue.4, pp.919-950, 2007. ,
DOI : 10.1185/030079906X162746
Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme, Current Medicinal Chemistry, vol.16, issue.23, pp.2943-51, 2009. ,
DOI : 10.2174/092986709788803114
Novo Nordisk Canada Inc. Mars, 2014. ,
Role and indication of GLP-1 analogues in the treatment of type 2 diabetes, Rev Med Suisse, vol.5, pp.1260-1262, 2009. ,
Pharmacology of GLP-1 Agonists: Describing the Therapeutic Potential to Patients, 2011. ,
Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes, Diabetes Care, vol.30, issue.6, pp.1487-93, 2007. ,
DOI : 10.2337/dc06-2375
Effects of glucagon-like peptide-1 receptor agonists on renal function, 2013. ,
Drug-drug interactions with glucagon-like peptide-1 receptor agonists. Epub, 2012. ,
Exenatide effects on statin pharmacokinetics and lipid response, Int. Journal of Clinical Pharmacology and Therapeutics, vol.45, issue.02, 2007. ,
DOI : 10.5414/CPP45114
Cross-Over Trial Investigating the Effect of Liraglutide on the Absorption Pharmacokinetics of Concomitantly Administered Oral Drugs in Healthy Subjects. http://professional.diabetes.org/Content/Posters, 2008. ,
Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial, BMC Clinical Pharmacology, vol.825, issue.1, 2012. ,
DOI : 10.1016/j.jchromb.2005.01.012
Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men, The Journal of Clinical Pharmacology, vol.9, issue.2, 2006. ,
DOI : 10.1177/0091270006291622
Effects of Multiple Doses of Albiglutide on the Pharmacokinetics, Pharmacodynamics, and Safety of Digoxin, Warfarin, or a Low-Dose Oral Contraceptive, Postgraduate Medicine, vol.687, issue.12 ,
DOI : 10.1177/0091270006291622
Pancréatites médicamenteuses, 2014. ,
GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Ann Endocrinol (Paris), pp.5-6515, 2013. ,
Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes, Diabetes Care, vol.28, issue.5, 2005. ,
DOI : 10.2337/diacare.28.5.1092
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes, Diabetes Care, vol.27, issue.11, p.113 ,
DOI : 10.2337/diacare.27.11.2628
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea, Diabetes Care, vol.28, issue.5, 2005. ,
DOI : 10.2337/diacare.28.5.1083
Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes, Annals of Internal Medicine, vol.143, issue.8, 2005. ,
DOI : 10.7326/0003-4819-143-8-200510180-00006
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland. subgroup data from a randomised multinational trial GWAA. GWAA Polish Study Group, p.24186595, 2010. ,
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26??weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type??2 diabetes (LEAD-1 SU), Diabetic Medicine, vol.284, issue.3, 2009. ,
DOI : 10.1111/j.1464-5491.2009.02666.x
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study, Diabetes Care, vol.32, issue.1, 2009. ,
DOI : 10.2337/dc08-1355
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial, The Lancet, vol.373, issue.9662, 2009. ,
DOI : 10.1016/S0140-6736(08)61246-5
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). LEAD-4 Study Investigators, 2009. ,
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6), The Lancet, vol.374, issue.9683, 2009. ,
DOI : 10.1016/S0140-6736(09)60659-0
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials, BMJ, vol.344, issue.jan10 2, p.7771, 2012. ,
DOI : 10.1136/bmj.d7771
Effects of glucagonlike peptide-1 receptor agonists on body weight: a meta-analysis, 2012. ,
Fiche(s) d'identité interopérable. Historique des références officielles ,
Effects of exenatide compared with twice-daily triphasic insulin aspart in patients with type 2 diabetes using metformin and a sulphonylurea, 42nd annual meeting of the European Association of the Study of Diabetes, p.1, 2006. ,
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study, International Journal of Obesity, vol.289, issue.11, pp.1443-51, 2013. ,
DOI : 10.1161/01.CIR.0000111245.75752.C6
Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic metaanalysis and meta-regression. janvier 2014 ,
Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus, 2014. ,
Alternative dosing strategies for liraglutide in patients with type 2 diabetes mellitus, American Journal of Health-System Pharmacy, vol.71, issue.3, 2014. ,
DOI : 10.2146/ajhp130301
Trends in the Epidemiology of the First Attack of Acute Pancreatitis, Pancreas, vol.33, issue.4, pp.323-353, 2006. ,
DOI : 10.1097/01.mpa.0000236733.31617.52
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1???Based Therapies, Gastroenterology, vol.141, issue.1, 2011. ,
DOI : 10.1053/j.gastro.2011.02.018
A cohort study of acute pancreatitis in relation to exenatide use, Diabetes, Obesity and Metabolism, vol.53, issue.6, 2011. ,
DOI : 10.1111/j.1463-1326.2011.01376.x
Glucagonlike Peptide 1???Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus, JAMA Internal Medicine, vol.173, issue.7, pp.534-543, 2013. ,
DOI : 10.1001/jamainternmed.2013.2720
Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. The French Pharmacovigilance Centers Networkhttp://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Diabete-de-type-2- nouvelles-donnees-sur-le-risque-pancreatique-chez-les-patients-diabetiques-traites-par-lesincretinomimetiques-Point-d-information (Dernière consultation, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-00922480
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies, BMJ, vol.348, issue.apr15 2, 2014. ,
DOI : 10.1136/bmj.g2366
Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population, Diabetes Technology & Therapeutics, vol.14, issue.10, pp.904-915, 2012. ,
DOI : 10.1089/dia.2012.0075
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs, Diabetes, Obesity and Metabolism, vol.50, issue.3, pp.273-278, 2014. ,
DOI : 10.1111/dom.12230
Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway. Mars, 2014. ,
The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review, Diabetes/Metabolism Research and Reviews, vol.360, issue.Suppl. 1, 2011. ,
DOI : 10.1002/dmrr.1202
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations, Expert Opinion on Drug Metabolism & Toxicology, vol.51, issue.1, 2012. ,
DOI : 10.2337/db10-1790
Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment, Diabetes, Obesity and Metabolism, vol.30, issue.6, 2012. ,
DOI : 10.1111/j.1463-1326.2012.01561.x
Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.6, pp.1695-702, 2011. ,
DOI : 10.1210/jc.2010-2822
Glucagon-like Peptide-1 receptor agonists activate rodent thyroid Ccells causing calcitonin release and C-cell proliferation, 2010. ,
Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland, The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.1, 2012. ,
DOI : 10.1210/jc.2011-2407
Do GLP-1?Based Therapies Increase Cancer Risk? http://care.diabetesjournals.org/content, pp.245-280 ,
Incretin Receptors in Non-Neoplastic and Neoplastic Thyroid C Cells in Rodents and Humans: Relevance for Incretin-Based Diabetes Therapy, Neuroendocrinology, vol.94, issue.4, 2011. ,
DOI : 10.1159/000330447
Should GLP-1 receptor agonists be used with caution in high risk population for colorectal cancer? 2013 Dec ,
GLP-1 receptor agonists and the risk of colorectal cancer, Medical Hypotheses, vol.82, issue.6 ,
DOI : 10.1016/j.mehy.2014.03.028
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice, AJP: Renal Physiology, vol.303, issue.7, 2012. ,
DOI : 10.1152/ajprenal.00259.2012
Effects of glucagon-like peptide-1 receptor agonists on renal function, 2013. ,
Observational Study of Kidney Function and Albuminuria in Patients With Type 2 Diabetes Treated With Exenatide BID Versus Insulin Glargine, Annals of Pharmacotherapy, vol.76, issue.5, 2014. ,
DOI : 10.1162/003465302317331982
Effect of a Single Cyclosporine Dose on the Single-Dose Pharmacokinetics of Sitagliptin (MK-0431), a Dipeptidyl Peptidase-4 Inhibitor, in Healthy Male Subjects, The Journal of Clinical Pharmacology, vol.57, issue.2, 2007. ,
DOI : 10.1177/0091270006296523
Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein, Journal of Pharmacology and Experimental Therapeutics, vol.321, issue.2, 2007. ,
DOI : 10.1124/jpet.106.116517
Erratum to: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions, Clinical Pharmacokinetics, vol.50, issue.1, 2010. ,
DOI : 10.1007/BF03257472
Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole, Clinical Pharmacology: Advances and Applications, 2011. ,
DOI : 10.2147/CPAA.S15227
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects, British Journal of Clinical Pharmacology, vol.17, issue.1, 2011. ,
DOI : 10.1111/j.1365-2125.2011.03937.x
Mécanisme d'action des inhibiteurs de la dipeptidyl-peptidase IV ,
Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema, Hypertension, vol.54, issue.3, 2009. ,
DOI : 10.1161/HYPERTENSIONAHA.109.134197
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus (Review) The Cochrane Collaboration, 2009. ,
Sitagliptin Study 024 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial, 2007. ,
Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin, 2007. ,
Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes: A 24-week, double-blind, randomized trial, Diabetes Care, vol.30, issue.2, 2007. ,
DOI : 10.2337/dc06-1815
Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study, Diabetes, Obesity and Metabolism, vol.49, issue.0, 2008. ,
DOI : 10.1111/j.1464-5491.2004.01426.x
Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin, 2008. ,
CV181-011 Study Investigators. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes, 2009. ,
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes, JAMA, vol.298, issue.2, 2007. ,
DOI : 10.1001/jama.298.2.194
Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. janvier 2014 ,
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis, BMJ, vol.344, issue.mar12 1, 2012. ,
DOI : 10.1136/bmj.e1369
The long-term efficacy and safety of DPP-IV inhibitors monotherapy and in combination with metformin in 18 980 patients with type-2 diabetes mellitus-a meta-analysis. Mars, 2014. ,
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. dec 2013 ,
Effects of incretin-based therapy in patients with heart failure and myocardial infarction, Endocrine, vol.44, issue.1 ,
DOI : 10.1007/s12020-014-0175-4
EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE), American Heart Journal, vol.162, issue.4, pp.620-626, 2011. ,
DOI : 10.1016/j.ahj.2011.08.004
Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes, Postgraduate Medicine, vol.110, issue.6, 2013. ,
DOI : 10.1016/S0140-6736(12)60691-6
Dual Inhibition of Dipeptidyl Peptidase IV and Aminopeptidase N Suppresses Inflammatory Immune Responses, Annals of the New York Academy of Sciences, vol.517, issue.1, pp.402-409, 2007. ,
DOI : 10.1084/jem.20042276
Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase. 2011; Diabetes Care, Feb, vol.34, issue.2, pp.369-74, 2011. ,
CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders, Mini-Reviews in Medicinal Chemistry, vol.7, issue.3, pp.253-73, 2007. ,
DOI : 10.2174/138955707780059853
Dipeptidyl Peptidase IV and Incident Diabetes: The Atherosclerosis Risk in Communities (ARIC) study, Diabetes Care, vol.33, issue.5, pp.1109-1120, 2010. ,
DOI : 10.2337/dc09-1996
Inflammatory Process in Type 2 Diabetes: The Role of Cytokines, Annals of the New York Academy of Sciences, vol.45, issue.1, pp.89-117, 2006. ,
DOI : 10.1074/jbc.M404962200
Infections in Patients with Diabetes Mellitus, New England Journal of Medicine, vol.341, issue.25 ,
DOI : 10.1056/NEJM199912163412507
Increased Risk of Common Infections in Patients with Type 1 and Type 2 Diabetes Mellitus Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study, pp.2012-38550, 2005. ,
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study, Diabetes Care, vol.32, issue.5, pp.834-842, 2009. ,
DOI : 10.2337/dc08-1755
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1???Based Therapies, Gastroenterology, vol.141, issue.1, 2011. ,
DOI : 10.1053/j.gastro.2011.02.018
Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials, Diabetes, Obesity and Metabolism, vol.11, issue.1, 2013. ,
DOI : 10.1111/dom.12176
Prescribing gliptins: Enthusiasm should be coupled with caution, Indian Journal of Endocrinology and Metabolism, vol.16, issue.2, 2012. ,
DOI : 10.4103/2230-8210.93785
One year of sitagliptin treatment protects against islet amyloid-associated ??-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice, AJP: Endocrinology and Metabolism, vol.305, issue.4, 2013. ,
DOI : 10.1152/ajpendo.00025.2013
Flow-mediated dilatation, 2000. ,
Dipeptidyl Peptidase-4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow-Mediated Vasodilatation in Type 2 Diabetic Patients, Journal of the American Heart Association, vol.2, issue.1 ,
DOI : 10.1161/JAHA.112.003277
Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin, Journal of the European Academy of Dermatology and Venereology, vol.161, issue.2, pp.249-53, 2012. ,
DOI : 10.1111/j.1468-3083.2011.04062.x
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial, International Journal of Clinical Practice, vol.154, issue.Suppl. 3, 2011. ,
DOI : 10.1111/j.1742-1241.2011.02656.x
Anorexigenic Effects of GLP-1 and Its Analogues, Handb Exp Pharmacol, vol.209, pp.185-207, 2012. ,
DOI : 10.1007/978-3-642-24716-3_8
Cardiovascular Biology of the Incretin System, Endocrine Reviews, vol.33, issue.2, pp.187-215, 2012. ,
DOI : 10.1210/er.2011-1052
The Efficacy and Tolerability of Exenatide in Comparison to Placebo; A Systematic Review and Meta-Analysis of Randomized Clinical Trials, Journal of Pharmacy & Pharmaceutical Sciences, vol.15, issue.1, pp.1-30, 2012. ,
DOI : 10.18433/J3G883
DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis, Advances in Therapy, vol.27, issue.1, pp.14-25, 2012. ,
DOI : 10.1007/s12325-011-0088-z
Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: Yes, European Journal of Internal Medicine, vol.23, issue.2, pp.126-157, 2012. ,
DOI : 10.1016/j.ejim.2011.10.007
Individualizing Glycemic Targets in Type 2 Diabetes Mellitus: Implications of Recent Clinical Trials, Annals of Internal Medicine, vol.154, issue.8, pp.554-563, 2011. ,
DOI : 10.7326/0003-4819-154-8-201104190-00007
Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control, International Journal of Clinical Practice, vol.358, issue.10, pp.1421-1426, 2009. ,
DOI : 10.1111/j.1742-1241.2009.02165.x
Goals of Glycemic Control in Frail Older Patients With Diabetes, JAMA, vol.305, issue.13, pp.1350-1351, 2011. ,
DOI : 10.1001/jama.2011.404
Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, vol.358, pp.2545-59, 2008. ,
Intensive glucose control and macrovascular outcomes in type 2 diabetes, Diabetologia, vol.359, issue.11, pp.2288-982470, 2009. ,
DOI : 10.1007/s00125-009-1470-0
Recommandations HAS-ANSM 2013 versus prise de position ADA-EASD 2012 : convergences et divergences ? SFD, 2013. ,
L'entretien: L'enquête et ses méthodes. 2 ème édition Armand colin, pp.2011-142 ,